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Top row: t(2;8)(p12;q24) G- banding (left and center) - Courtesy Diane H.Norback, Eric B. Johnson, Sara Morrison-Delap; R- banding - 
(right) Courtesy Jean-Luc Lai. 
Middle row: t(8;14)(q24;q32) G- banding - (left) Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap; R- banding - (center 
Courtesy Jean-Luc Lai; right: Editor). 
Lower row: t(8;22)(q24;q11) G- banding (left and center) - Courtesy Diane H. Norback, Eric B.Johnson, Sara Morrison-Delap UW 
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Bone marrow sample: the medium-sized cells show a diffuse monotonous pattern of infiltration. The nuclei are round, cytoplasm deeply 
basophilic and usually contain vacuoles. The morphological feature in this bone marrow smear (Giemsa), quite similar to tumor cells as 
seen in tissue imprints, is highly characteristic of Burkitt lymphoma - Courtesy Georges Flandrin.
.
Clinics and pathology 
Disease 
Described both in B-cell acute lymphoblastic leukemia 
(ALL) and in non-Hodgkin lymphomas (NHL), 
especially in the Burkitt lymphoma. 
Phenotype/cell stem origin 
B-cell malignant hemopathies. 
Epidemiology 
Of the lymphoma: the translocation is present in both 
the endemic African Burkitt lymphoma and in the non 
endemic tumor type (Europe, America, Japan); the L3-
ALL represents only 2% of ALLs and is closer to a 
leukemic stage of a lymphoma than to other ALL types. 
Cytology 
ALL: L3 morphology according to the FAB 




t(8;14) is described in 75-85% of the cases, t(2;8) in 
5%, and t(8 ;22) in the remaining 10%; high-quality 
metaphases are required to detect t(8;14) and t(8;22). 
 
944B18 The figure illustrates the translocation of the c-Myc 
gene (probe 944B18, red) to 14q32.3 - Courtesy Mariano 
Rocchi,  
Additional anomalies 
Reported in 70% cases, especially: structural 
rearrangements of the long arm of chromosome 1 (30% 
cases) resulting in a partial trisomy 1q, rearrangements 
of 13q34 (15% cases); a t(1;13)(q23;q34) has been 
described. 
Variants 
t(2;8)(p12;q24) and t(8;22)(q24;q11) are variants of the 
t(8;14)(q24;q32); three-way rearrangements and 
translocations of submicroscopic chromosome 
fragments have also been described. 
Genes involved and proteins 
Note 
On the molecular point of view, in all these three 
translocations, the oncogene C-MYC is juxtaposed 
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either with the immunoglobulin heavy chain locus IGH 
(14q32), the kappa light-chain locus IGK (2p12), or the 
lambda light-chain locus IGL (22q11); all these 






The human C-MYC oncogene is the cellular 
homologue of an avian retrovirus; in vertebrates, it 
belongs to a small gene family with closely related 
members (C-MYC, N-MYC, L-MYC); C-MYC has 
three exons; two promoters P1 and P2 control the C-
MYC transcription; the choice of the promoter depends 
on the myc protein level. P2 promoter is considered as 
the most active promoter, generating a 2.25 kb 
transcript, whereas P1 promoter enrates a 2.4 kb 
transcript; the main part of 5' first exon corresponds to 
an untranslated region, MYC1 translation starting at a 
CUG codon near its 3' end, having 14 additional N-
terminal amino-acids compared with MYC2 translation 
site localized 5' near the second exon beginning. 
Protein 
Myc protein is a transcription factor of the helix-loop-
helix/leucine zipper family that activates transcription 
as obligate heterodimer with a partner protein, Max. 
Immunoglobulin genes : IGH, IGK, IGL 
Location 
Located in 14q32, 2p12 and 22q11 respectively. 




No hybrid gene but the translocation of C-MYC close 
to enhancers constitutively active in this specific cell 
lineage. 
Description 
C-MYC is translocated to der(14) in the t(8;14), 
whereas it remains on der(8) in the variant 
translocations; t(8;14) leads to a head-to-head fusion of 
C-MYC with the heavy chain immunogloulin locus: 
8q24 is close to the 5' extremity of C-MYC exon 2, 
leading the all translated gene region to 14q32; the  
8q24 breakpoint region is variable, scattered over a 190 
Kb region, 5' far from C-MYC or within C-MYC; the 
14q32 breakpoint region is mainly located in the 
constant region, very close within the switch or joining 
regions; C-MYC juxtaposed to the immunoglobin 
constant regions and enhancer is overexpressed, 
shutting down the normal remaining C-MYC; in both 
t(2;8) and t(8;22), the breakpoint is in 3' of or distal to 
the C-MYC gene which always remains on der(8); the 




The protein c-myc resulting from the translation of the 
second and third exons, through DNA- binding 
properties, plays a role in regulating cell growth and 
differentiation. 
Oncogenesis 
Constitutive expression of c-myc induces proliferation 
even in the absence of growth factors. 
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